Why Employers Are Pulling Back Now

For most employers, this is a math problem. Pharmacy spending now makes up 25% of employers’ total health spending, and drug costs are projected to rise 12%, according to an industry analysis reported by Insurance Business in September 2026. Brenna Shebel of the Business Group on Health put it bluntly: “The result is greater scrutiny of every healthcare dollar spent.” Eileen Pincay of Segal summed up the dilemma: “GLP-1s work, employees want them, and they’re extremely expensive.”

Falling prices have not solved the problem for employers. Louis Zollo of Segal told Reuters, “Even though we have seen the unit cost come down, the patient population keeps growing.” Employers also complain that their pharmacy benefit manager contracts do not deliver the low prices cash-paying customers now get directly from drugmakers. Starbucks said in August 2026 that it would stop covering GLP-1s for weight loss starting in October, while continuing coverage for diabetes and other approved conditions. Cigna ended weight-loss coverage for its own employees in July.

Why the Numbers Look So Different

The surveys measure different groups. Business Group on Health members are mostly very large companies, which are more likely to offer generous benefits. KFF’s 2025 survey found that only 19% of firms with 200 or more workers covered GLP-1s for weight loss in their largest plan, compared with 43% of firms with 5,000 or more workers. If you work for a midsize company, your chances of having coverage were always lower, and the trend now points downward even at the biggest employers.

Read the Fine Print Before You Pay Cash

“Dropped coverage” does not always mean every GLP-1 is off the table. Most cuts apply only when the drug is prescribed for weight loss. Starbucks, for example, said coverage continues for diabetes and other approved conditions. That distinction matters because several of these drugs now carry FDA approvals beyond weight management.

Other Approved Uses That May Still Be Covered

Semaglutide and tirzepatide are approved for type 2 diabetes under the brand names Ozempic and Mounjaro. Wegovy also carries FDA approval to reduce the risk of heart attack and stroke in adults with heart disease and obesity or overweight, and Zepbound is approved for moderate to severe obstructive sleep apnea in adults with obesity. If one of these conditions applies to you, ask your doctor whether a prescription for that use could be covered under your plan’s rules. Your plan decides, and it may require prior authorization and documentation, so ask your benefits department or insurer for the exact wording of the exclusion.

Your Right to Appeal

Under Affordable Care Act rules, most job-based plans must let you file an internal appeal within 180 days of a denial, and if the plan upholds it, you can generally request an independent external review within four months. An appeal is strongest when a prescription is for a covered condition or when your doctor documents medical necessity. If the plan document clearly excludes weight-loss drugs, an appeal is unlikely to overturn the exclusion itself, but it costs nothing but time to ask, and plans sometimes grant exceptions.

What GLP-1s Cost Without Insurance in Late 2026

Cash prices have changed dramatically. After deals with the White House announced in November 2025, Novo Nordisk and Eli Lilly lowered prices for people paying out of pocket, and the government’s TrumpRx.gov site launched on February 5, 2026, to point consumers to those offers. Oral options arrived too: Wegovy’s pill launched in January 2026 and Lilly’s Foundayo, or orforglipron, followed in April. Both start at about $149 a month through the drugmakers’ direct websites.

A few details are easy to miss. Wegovy’s $199 introductory price applies to the first two fills of the lowest doses for eligible new patients and runs through December 31, 2026. Lilly’s $449 price for higher Zepbound doses depends on refilling within 45 days; The RX Index reported that late refills can push the price to $499 to $699. The pills cost less but produce somewhat less weight loss on average, about 14% for the Wegovy pill and 11% for Foundayo in clinical trials, according to Reuters.

Your Options, Side by Side

The right move depends on your diagnosis, your dose, your household’s other coverage and your budget. This table compares the main paths. Prices are as of September 2026 and can change without notice; confirm with the manufacturer or TrumpRx.gov.

The HSA savings range above is indicative and depends on your federal and state tax brackets and whether you pay payroll tax on the money. The IRS treats prescription drugs for a diagnosed condition, including obesity, as qualified medical expenses, but check with your plan administrator before using account funds.

Turning Open Enrollment Into a Decision Point

Open enrollment, typically in November for calendar-year plans, is your one guaranteed window to switch. If your spouse or partner’s employer still covers GLP-1s for weight loss, compare the extra premium for joining that plan with roughly $3,600 to $5,400 a year in cash costs. Ask for the plan’s drug list, called a formulary, and the specific criteria, such as BMI thresholds or required lifestyle programs. KFF found 34% of large firms covering these drugs now require participation in a lifestyle or clinical program first, up from 10% in 2024.

A Step-by-Step Plan for the Next 60 Days

1. Get the exact policy languageAsk HR or your insurer when coverage ends and whether diabetes, heart or sleep apnea uses remain covered.
2. Book a visit with your prescriberReview your diagnoses, current dose and whether another approved use or a pill makes sense.
3. File an appeal if your doctor supports itSubmit within 180 days of a denial, with records showing medical necessity.
4. Compare plans at open enrollmentCheck a spouse’s formulary and price the premium difference against cash costs.
5. Fund an HSA or FSASet contributions to cover the year’s drug costs with pre-tax dollars where eligible.
6. Price self-pay before your last covered fillLine up a manufacturer or TrumpRx order so you do not have a gap in treatment.

Older Workers and Medicare

If you are 65 or older or about to retire, the picture is different. Medicare’s GLP-1 Bridge, which runs from July 1, 2026, through December 31, 2027, charges a $50 monthly copay for weight-management use for eligible Part D enrollees who meet clinical criteria and receive prior authorization. It covers Wegovy and Foundayo formulations and the Zepbound KwikPen, but not Zepbound vials, according to The RX Index’s review of CMS materials. If you are still working past 65 with employer coverage, ask a benefits counselor how your employer plan and Medicare coordinate before making changes.

How the Year Unfolded

1. November 2025White House announces pricing deals with Eli Lilly and Novo Nordisk for GLP-1 drugs.
2. January 2026Wegovy pill launches at a starting self-pay price of about $149 a month.
3. February 5, 2026TrumpRx.gov launches to steer cash-paying patients to discounted prices.
4. April 2026Lilly’s Foundayo pill launches, also starting at about $149 a month.
5. July 2026Medicare GLP-1 Bridge begins at $50 a month; Cigna ends weight-loss coverage for its employees.
6. October 2026Starbucks ends weight-loss coverage for benefits-eligible workers.
7. November 2026Open enrollment for most 2027 plans; more employers announce cuts.
8. December 31, 2026Wegovy’s $199 introductory offer is scheduled to end.
9. December 31, 2027Medicare GLP-1 Bridge is scheduled to end.

What Could Change Next

Employers are watching two forces. Cheaper pills could lower the cost per person, but 87% of Business Group on Health members expect pills to raise overall demand, which could offset the savings. Dan Mendelson of Morgan Health told Reuters the pills will lower per-treatment costs, but “on aggregate this still represents a major cost driver for employers.” Some employers may shift to narrower coverage instead of dropping it, using BMI thresholds, required lifestyle programs or coverage limited to specific conditions.

• Check the exclusion wordingWeight loss only, or all uses
• Appeal within 180 daysExternal review within 4 months
• Compare cash prices$149 to $449 a month
• Refill within 45 daysTo keep Lilly’s lower price
• Use HSA or FSA moneyPay with pre-tax dollars
• Avoid unverified online sellersUse licensed pharmacies only